Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBT Margin (2016 - 2026)

Standard Biotools has reported EBT Margin over the past 16 years, most recently at 25.8% for Q4 2025.

  • Quarterly EBT Margin fell 13260.0% to 25.8% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67.26% through Dec 2025, down 3245.0% year-over-year, with the annual reading at 80.31% for FY2025, 5367.0% down from the prior year.
  • EBT Margin was 25.8% for Q4 2025 at Standard Biotools, up from 168.27% in the prior quarter.
  • Over five years, EBT Margin peaked at 158.4% in Q4 2024 and troughed at 346.98% in Q2 2022.
  • The 5-year median for EBT Margin is 70.33% (2024), against an average of 81.81%.
  • Year-over-year, EBT Margin skyrocketed 47493bps in 2021 and then crashed -29004bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 53.55% in 2021, then tumbled by -44bps to 76.88% in 2022, then soared by 195bps to 73.25% in 2023, then skyrocketed by 116bps to 158.4% in 2024, then tumbled by -84bps to 25.8% in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBT Margin are 25.8% (Q4 2025), 168.27% (Q3 2025), and 84.01% (Q2 2025).